-
1 Comment
Biohaven Pharmaceutical Holding Company Ltd is currently in a long term uptrend where the price is trading 19.7% above its 200 day moving average.
From a valuation standpoint, the stock is 95.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 63.0.
Biohaven Pharmaceutical Holding Company Ltd's total revenue rose by inf% to $35M since the same quarter in the previous year.
Its net income has dropped by 45.9% to $-218M since the same quarter in the previous year.
Finally, its free cash flow fell by 107.7% to $-213M since the same quarter in the previous year.
Based on the above factors, Biohaven Pharmaceutical Holding Company Ltd gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| Exchange | NYSE |
| CurrencyCode | USD |
| ISIN | VGG111961055 |
| Beta | 4.15 |
|---|---|
| Market Cap | 2B |
| PE Ratio | None |
| Target Price | 61 |
| Dividend Yield | None |
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BHVN using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
